On May 15, 2024 Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, reported that the latest results from five studies have been selected for Poster Presentations at the 2024 European Hematology Association (EHA) (Free EHA Whitepaper) Hybrid Congress (EHA 2024) (Press release, Ascentage Pharma, MAY 15, 2024, View Source;results-from-five-studies-of-ascentage-pharmas-key-drug-candidates-selected-for-presentations-at-2024-european-hematology-association-hybrid-congress-302147047.html [SID1234643370]). These posters will feature olverembatinib (HQP1351), the first and only China-approved third-generation BCL-ABL1 inhibitor; investigational lisaftoclax (APG-2575), a Bcl-2 selective inhibitor; and investigational APG-5918, an EED selective inhibitor.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The European Hematology Association (EHA) (Free EHA Whitepaper) Hybrid Congress is the largest gathering of the hematology field in Europe. It showcases the most cutting-edge research and state-of-the-art innovative therapies, attracting over 10,000 clinical experts and researchers from more than 100 countries every year. This year, the EHA (Free EHA Whitepaper) Hybrid Congress will take place on June 13 – 16, 2024, in Madrid, Spain.
"I am delighted to showcase the strength and progress of Ascentage Pharma in hematology at this year’s congress, especially the therapeutic potential and clinical value of its drug candidates in chronic myeloid leukemia (CML), Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), multiple myeloma (MM), immunoglobulin light-chain (AL) amyloidosis, and anemia diseases," said Dr. Yifan Zhai, Chief Medical Officer of Ascentage Pharma. "We look forward to sharing the detailed results at the congress. In the future, we will continue to advance those development programs in efforts to bring more treatment options to patients around the world."
The five studies to be presented at EHA (Free EHA Whitepaper) 2024 are as follows:
Olverembatinib
Olverembatinib Overcomes Ponatinib and Asciminib Resistance in Patients (Pts) with Heavily Pretreated Chronic Myeloid Leukemia (CML) and Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph⁺ ALL)
• Abstract#: P722
• Presentation Type: Poster presentation
• Topic: Chronic myeloid leukemia – Clinical
• Date & Time: Friday June 14, 2024, 18:00 – 19:00 CEST
• Presenting Author: Dr. Elias Jabbour, The University of Texas MD Anderson Cancer Center
Combination of Third Generation TKI Olverembatinib and Chemotherapy or Blinatumomab for New Diagnosed Adult Ph+ ALL Patients
• Abstract#: P427
• Presentation Type: Poster presentation
• Topic: Acute lymphoblastic leukemia – Clinical
• Date & Time: Friday June 14, 2024, 18:00 – 19:00 CEST
• Presenting Author: Junjie Chen, Nanfang Hospital, Southern Medical University
Patient Reported Outcomes in Adults with TKI-Resistant Chronic Myeloid Leukemia Receiving Olverembatinib-Therapy
• Abstract#: P1862
• Presentation Type: e-Poster presentation
• Topic: Chronic myeloid leukemia – Clinical
• Date & Time: Friday June 14, 2024, 18:00 – 19:00 CEST
• Presenting Author: Lu Yu, Peking University People’s Hospital
Lisaftoclax
Lisaftoclax (APG-2575) Combined with Novel Therapeutic Regimens in Patients (Pts) with Relapsed or Refractory (R/R) Multiple Myeloma (MM) or Immunoglobulin Light-Chain (AL) Amyloidosis
• Abstract#: P917
• Presentation Type: Poster presentation
• Topic: Myeloma and other monoclonal gammopathies – Clinical
• Date & Time: Friday June 14, 2024, 18:00 – 19:00 CEST
• Presenting Author: Dr. Sikander Ailawadhi, Mayo Clinic Florida
APG-5918
Embryonic Ectoderm Development (EED) Inhibitor APG-5918 Improves Chronic Kidney Disease- (CKD)-Induced Hemoglobin (HB) Insufficiency in Preclinical Models of Anemia
• Abstract#: P1550
• Presentation Type: Poster presentation
• Topic: Enzymopathies, membranopathies and other anemias
• Date & Time: Friday June 14, 2024, 18:00 – 19:00 CEST
• Presenting Author: Dr. Eric Liang, Ascentage Pharma Group Inc.